Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma

Amitani, R; Suzuki, Kazuyuki; Tanaka, Eisaku; Murayama, Takako; Kuze, Fumiyuki

doi:10.1046/j.1365-2222.1998.00217.x

Cited by 96 publications

(63 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum level of ECP is known to be a marker of activated eosinophils in patients with bronchial asthma (Venge et al 1999). Increased serum ECP levels in asthma patients in the present study are consistent with the levels in a previous report in symptomatic asthma patients (Niimi et al 1998).…”

Section: Discussionsupporting

confidence: 82%

“…The levels of these factors at the exacerbations caused by URTIs did not differ from those in patients with acute asthma without obvious URTIs. The levels of these factors are consistent with the data as previously described in acute asthma without obvious URTIs (Montefort et al 1994;Yokoyama et al 1995; Niimi et al 1998). These findings, therefore, suggest that virus infection may also produce the factors that induce inflammation and bronchospasm observed in acute asthma caused by other than virus infection.…”

Section: Discussionsupporting

confidence: 81%

“…Increased circulating serum levels of IL-6 (Hashimoto et al 1994;Yokoyama et al 1995), soluble intercellular adhesion molecule-1 (sI-CAM-1) (Montefort et al 1994) and ECP (Niimi et al 1998), and concentrations of urine leukotriene E 4 (LTE 4 ) (Oosaki et al 1997) and plasma histamine (Calhoun et al 1991) have been reported in symptomatic acute asthma (Montefort et al 1994;Yokoyama et al 1995;Oosaki et al 1997;Niimi et al 1998), in children with acute respiratory infection (Hashimoto et al 1994), and in experimental RV infection in allergic subjects after antigen bronchoprovocation (Calhoun et al 1991). However, the relationship between the airway narrowing and the increases in these factors has not been studied in patients with asthma exacerbations caused by spontaneously developed upper respiratory tract infections (URTIs).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Inflammatory and Bronchospastic Factors in Asthma Exacerbations Caused by Upper Respiratory Tract Infections

Yasuda

Suzuki

Zayasu

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

It is still uncertain how viral respiratory infections cause acute exacerbations of bronchial asthma, although several mechanisms have been proposed. We studied the relationship between the airway narrowing and the inflammatory and bronchospastic factors in peripheral venous blood and urine, in 30 patients with asthma at the exacerbations caused by upper respiratory tract infections (URTIs). Acute exacerbations caused decreases in peak expiratory flow rate (PEFR) in all 30 patients with asthma. Asthma exacerbations caused the rises in serum levels of interleukin-6, soluble intercellular adhesion molecule-1 and eosinophil cationic protein, concentrations of urinary leukotriene E 4 and plasma histamine, compared with those in patients with asthma at a stable condition and those in 30 control subjects (p < 0.05). The values of PEFR at the exacerbations correlated with the levels of these factors. Treatment with oral glucocorticoids reversed the decreases in PEFR and the increases in these factors. At the onset of URTIs, rhinovirus and influenza type A virus were identified in 13 and 7 patients, respectively. Each of parainfluenza virus, adenovirus, and enterovirus was identified in one patient. These findings suggest that respiratory viral infections may cause acute asthma exacerbations via the production of mediators that induce inflammation and bronchospasm. bronchial asthma; virus infection; interleukin-6; ICAM-1; leukotriene; histamine

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 81%

mentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory and Bronchospastic Factors in Asthma Exacerbations Caused by Upper Respiratory Tract Infections

Yasuda

Suzuki

Zayasu

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…A previous study has suggested that serum ECP reflects the degree of eosinophilic inflammation in the airways and the disease activity in asthma [21]. Three studies examining the correlations between serum and sputum ECP levels showed contrasting results, since CLAMAN et al [22] found a positive correlation, whereas VIRCHOW et al [23], and, more recently, PIZZICHINI et al [24] failed to find such correlations.…”

Section: Discussionmentioning

confidence: 68%

Neutrophil CD11b and soluble ICAM-1 and E-selectin in community acquired pneumonia

Glynn¹,

Coakley²,

Kilgallen³

et al. 1999

Eur Respir J

View full text Add to dashboard Cite

Exhaled nitric oxide and eosinophil sputum markers are considered noninvasive ways in which to evaluate airway inflammation in asthma. The aim of this study was to evaluate the relationships between these methods of evaluation in asthmatic children.In a cross-sectional study of 25 mild±moderate asthmatic children (aged 6±13 yrs, 10 patients on inhaled steroids) exhaled NO was measured along with induced sputum by inhalation of hypertonic saline solution. The sputum was processed for eosinophil count and eosinophil cationic protein (ECP) determination. Serum ECP and lung function (forced expiratory volume in one second (FEV1)) were also measured.A significant correlation was observed between exhaled NO and sputum eosinophils (r=0.438, p=0.032) as well as between sputum eosinophils and sputum ECP (r=0.532, p<0.01). No correlation was observed among exhaled NO and serum ECP, sputum ECP, FEV1, respectively. Furthermore no correlation was observed between sputum eosinophil (%) and serum ECP and between sputum eosinophils and FEV1. There was no correlation among the investigated parameters in children treated with inhaled steroids.In conclusion, exhaled NO and sputum eosinophil counts are concordant in evaluating the degree of airway inflammation in patients with mild-to-moderate asthma. However, the association between these two noninvasive markers becomes less in steroid treated patients. Eur Respir J 1999; 13: 1386±1390.

show abstract

“…Due to its ability to reducing the number of mast cells and eosinophil, weakening eosinophilic activation, and lowering hyper-responsiveness of airways, glucocorticoids have been widely administered as primary drugs for treating chronic and acute BA (Barnes 2011). Serum ECP is a low molecular weight cationic basic protein and is secreted by activated eosinophils that can be functioned as a reference parameter for the evaluation of asthma severity (Niimi et al 1998). In this study, we explored the diagnostic efficiency of serum ECP on the efficacy of ICS therapy in children with BA with the underlying incentive to provide a better clinical evaluation for asthma severity.…”

Section: Discussionmentioning

confidence: 99%

Serum Eosinophil Cationic Protein Is a Useful Marker for Assessing the Efficacy of Inhaled Corticosteroid Therapy in Children with Bronchial Asthma

Guo

Sun

Wang

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Bronchial asthma (BA) is a chronic inflammatory disorder of airways for which the effective therapies include inhaled corticosteroids (ICS) and short-acting β 2-adrenoreceptor agonist (SABA). Serum eosinophil cationic protein (ECP) has been reported to reflect the degree of airway inflammation. We, therefore, explored the implication of serum ECP in assessing the efficacy of ICS therapy in BA children. Our prospective randomized control study enrolled 126 BA children and 78 healthy children (the control group). The BA patients were randomly assigned as two groups; 59 children were treated with ICS, twice a day, for three months and 67 patients received SABA inhalation only if necessary. After the 3-month therapy, the serum levels of ECP, endothelin-1, and nitric oxide and the eosinophil percentage (EOS%) in induced sputum were significantly lower in the ICS group, compared with the SABA group, but were still higher than the control group (all P < 0.05). The forced expiratory volume (FEV1%pred) and forced vital capacity (FEV1/FVC) were improved to the levels of the control group after therapy. Pearson correlation analysis presented that higher serum ECP levels were associated with higher EOS% in serum and with lower pulmonary function indices (FEVl%pred and FEV1/FVC). Importantly, the ICS group exhibited higher quality of life scores and lower symptom scores compared with the SABA group (all P < 0.05). ROC results revealed the diagnostic efficiency of serum ECP levels on the efficacy of ICS. In conclusion, measuring serum ECP levels is helpful for assessing the efficacy of ICS therapy in BA children.

show abstract

Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma

Abstract: The data suggest that serum ECP level reflects the intensity of eosinophilic airway inflammation, as well as the disease activity, and may be useful as an inflammatory marker in asthma.

Cited by 96 publications

References 27 publications

Inflammatory and Bronchospastic Factors in Asthma Exacerbations Caused by Upper Respiratory Tract Infections

Inflammatory and Bronchospastic Factors in Asthma Exacerbations Caused by Upper Respiratory Tract Infections

Neutrophil CD11b and soluble ICAM-1 and E-selectin in community acquired pneumonia

Serum Eosinophil Cationic Protein Is a Useful Marker for Assessing the Efficacy of Inhaled Corticosteroid Therapy in Children with Bronchial Asthma

Contact Info

Product

Resources

About